Status:
RECRUITING
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Lead Sponsor:
Amgen
Collaborating Sponsors:
AstraZeneca
Conditions:
Small-cell Lung Cancer
Extensive Stage Small-cell Lung Cancer
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolon...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
August 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 15 2029
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT07005128
Start Date
August 18 2025
End Date
July 15 2029
Last Update
February 27 2026
Active Locations (131)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Bernards Medical Center
Jonesboro, Arkansas, United States, 72401
2
University of California Los Angeles
Santa Monica, California, United States, 90404
3
Presbyterian Intercommunity Hospital Health Whitter Hospital
Whittier, California, United States, 90602
4
Yale New Haven Hospital
New Haven, Connecticut, United States, 06510